Bildkälla: Stockfoto

BioInvent: BI-1808 Shown to Be Safe as Monotherapy - Redeye

Redeye comments on BioInvent’s completed dose escalation (part A) in the phase I/IIa trial of BI-1808 in advanced cancer.

Redeye comments on BioInvent’s completed dose escalation (part A) in the phase I/IIa trial of BI-1808 in advanced cancer.
Börsvärldens nyhetsbrev
ANNONSER